Skip to Main Content

Author Details

Adam Sharp
The Institute for Cancer Research
2003
70
27
PMIDPaper TitleJournal TitlePublished Year
36114082B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.Eur Urol2023
37751307The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer.J Clin Invest2023
37520743Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy.Cancer Res Commun2023
37844613Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.Nature2023
37652207Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer.Lab Invest2023
37460872The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells.Nat Cancer2023
37087376PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.Eur Urol2023
37284046Germline <i>ATM</i> Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer.Eur Urol Open Sci2023
36964041Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38].Eur Urol2023
36609007A Transgender Patient with Prostate Cancer: Lessons Learnt.Eur Urol2023
36725887Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.Oncogene2023
34449248A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer.Annu Rev Pharmacol Toxicol2022
35695870Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clin Cancer Res2022
35491356Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer.Eur Urol Oncol2022
35552383Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.Clin Cancer Res2022
32988971Characterizing CDK12-Mutated Prostate Cancers.Clin Cancer Res2021
33516656AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.Cancer Treat Res Commun2021
33542074Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies.Clin Cancer Res2021
33822745JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.Cancer Res2021
35008216Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer.Cancers (Basel)2021
34753775HER3 Is an Actionable Target in Advanced Prostate Cancer.Cancer Res2021
34103179Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.Eur Urol2021
34066080Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.Cancers (Basel)2021
34061561Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer.Am Soc Clin Oncol Educ Book2021
33176972Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.Eur Urol2021
32343676The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer.J Clin Invest2020
32653323Elucidating Durable Responses to Immune Checkpoint Inhibition.Eur Urol2020
32250342CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.J Clin Invest2020
32414837Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.Cancer Res2020
30334814Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.J Clin Invest2019
30257982RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2019
31265359Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer.J Clin Oncol2019
31345636Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer.Eur Urol2019
31043708Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer.Oncogene2019
30952632Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.Cancer Res2019
31036442Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.Eur Urol2019
30340782Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.Eur Urol2019
28866255Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.Eur Urol2018
30135575Alternative splicing in prostate cancer.Nat Rev Clin Oncol2018
29911685Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.Eur Urol Oncol2018
30179225Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.J Clin Invest2018
30068710SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.Clin Cancer Res2018
30093450Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.Clin Cancer Res2018
29955776Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail.JAMA Oncol2018
29950727IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.Nature2018
30382943Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.J Clin Invest2018
29555663Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).Clin Cancer Res2018
29346775BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.Cell Rep2018
28606735Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.Clin Genitourin Cancer2017
28450425Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.Cancer Discov2017
  • 1 - 50 of 70

Recommended Authors

George V Thomas
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2016
Number of shared co-authors 7
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 8
Matti Annala
University of British Columbia
Career Start Year 2011
Number of shared co-authors 15
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 33
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 10
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 12
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 8
Gerhardt Attard
The Institute of Cancer Research
Career Start Year 2004
Number of shared co-authors 46
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 45
Rahul Aggarwal
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 27
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 25
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 13
Luke A Selth
Adelaide Medical School, University of Adelaide
Career Start Year 2002
Number of shared co-authors 11
Antonio Hurtado-Coll
University of British Columbia
Career Start Year 2002
Number of shared co-authors 11
Heather H Cheng
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 2002
Number of shared co-authors 41
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 20
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 7
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 22
Kim N Chi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 31
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 25
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 20
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 10
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 34
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 37
Evan Y Yu
University of Washington and Fred Hutchinson Cancer Research Center
Career Start Year 1997
Number of shared co-authors 42
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 15
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 11
Edwin M Posadas
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 19
Christopher P Evans
University of California Davis
Career Start Year 1988
Number of shared co-authors 27
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 47

Collaborators

Johann S de Bono
The Institute for Cancer Research
Co-authored papers 53
Wei Yuan
The Institute for Cancer Research
Co-authored papers 34
Suzanne Carreira
The Institute of Cancer Research
Co-authored papers 25
Susana Miranda
The Institute of Cancer Research
Co-authored papers 20
Alec Paschalis
The Institute for Cancer Research
Co-authored papers 17
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Co-authored papers 15
Nina Tunariu
The Institute of Cancer Research
Co-authored papers 14
Maryou B Lambros
The Institute of Cancer Research
Co-authored papers 13
Stephen R Plymate
University of Washington
Co-authored papers 11
Zafeiris Zafeiriou
Theageneion Anticancer Hospital
Co-authored papers 9
Penny Flohr
The Institute of Cancer Research
Co-authored papers 8
Gunther Boysen
Co-authored papers 8
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 7
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 7
Matthew Clarke
Co-authored papers 6
Ganesh V Raj
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 5
Colm Morrissey
Co-authored papers 4
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 3
Ilsa Coleman
Fred Hutchinson Cancer Center
Co-authored papers 3
Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Co-authored papers 3
Ram S Mani
UT Southwestern Medical Center
Co-authored papers 3
Mark A Rubin
University of Bern
Co-authored papers 3
Wassim Abida
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 3
Niven Mehra
Radboud university medical center
Co-authored papers 3
Raquel Perez-Lopez
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 3
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 2
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 2
Holger Moch
University Hospital Zurich
Co-authored papers 2
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Release 1.2